Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

617 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Clinical and Correlative Study of Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd) for Lenalidomide Refractory Multiple Myeloma in First Relapse.
Bhutani M, Foureau DM, Robinson M, Guo F, Fesenkova K, Atrash S, Paul B, Varga C, Friend R, Pineda-Roman M, Rigby K, Symanowski JT, Norek S, Tucker MR, Druhan LJ, Voorhees PM, Usmani SZ. Bhutani M, et al. Clin Lymphoma Myeloma Leuk. 2023 Jul;23(7):535-544.e1. doi: 10.1016/j.clml.2023.03.016. Epub 2023 Apr 7. Clin Lymphoma Myeloma Leuk. 2023. PMID: 37127471 Clinical Trial.
Bone marrow Ki-67 index is of prognostic value in newly diagnosed multiple myeloma.
Atrash S, Robinson M, Taneja A, Paul B, Cassetta K, Ndiaye A, Varga C, Block J, Lipford EH, Smith ET, McCall CM, Thurston V, Foureau D, Usmani SZ, Voorhees PM, Bhutani M. Atrash S, et al. Among authors: bhutani m. Eur J Haematol. 2023 Sep;111(3):373-381. doi: 10.1111/ejh.14016. Epub 2023 Jun 13. Eur J Haematol. 2023. PMID: 37311695
MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma.
Bhutani M, Robinson M, Foureau D, Atrash S, Paul BA, Guo F, Grayson J, Ivanina-Foureau A, Pineda-Roman M, Varga C, Friend R, Ferreri CJ, Begic X, Norek S, Drennan T, Anderson MB, Symanowski JT, Voorhees PM, Usmani SZ. Bhutani M, et al. Blood Adv. 2024 Nov 22:bloodadvances.2024014417. doi: 10.1182/bloodadvances.2024014417. Online ahead of print. Blood Adv. 2024. PMID: 39576965
Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma.
Einsele H, Moreau P, Bahlis N, Bhutani M, Vincent L, Karlin L, Perrot A, Goldschmidt H, van de Donk NWCJ, Ocio EM, Martinez-Lopez J, Rodríguez-Otero P, Dytfeld D, Diels J, Strulev V, Haddad I, Renaud T, Ammann E, Cabrieto J, Perualila N, Gan R, Zhang Y, Parekh T, Albrecht C, Weisel K, Mateos MV. Einsele H, et al. Among authors: bhutani m. Adv Ther. 2024 Apr;41(4):1576-1593. doi: 10.1007/s12325-024-02797-x. Epub 2024 Feb 24. Adv Ther. 2024. PMID: 38402374 Free PMC article.
Phase 1 first-in-human study of MEDI2228, a BCMA-targeted ADC, in patients with relapsed refractory multiple myeloma.
Dimopoulos MA, Migkou M, Bhutani M, Ailawadhi S, Kalff A, Walcott FL, Pore N, Brown M, Wang F, Cheng LI, Kagiampakis I, Williams M, Kinneer K, Wu Y, Jiang Y, Kubiak RJ, Zonder JA, Larsen J, Sirdesai S, Yee AJ, Kumar S. Dimopoulos MA, et al. Among authors: bhutani m. Leuk Lymphoma. 2024 Dec;65(12):1789-1800. doi: 10.1080/10428194.2024.2373331. Epub 2024 Oct 15. Leuk Lymphoma. 2024. PMID: 39404476 Free article. Clinical Trial.
Disparities in multiple myeloma among African Americans.
Bhutani M, Lonial S, Mikhael J. Bhutani M, et al. J Natl Med Assoc. 2023 May;115(2S):S26-S31. doi: 10.1016/j.jnma.2022.10.001. Epub 2022 Dec 22. J Natl Med Assoc. 2023. PMID: 36566137 No abstract available.
Mechanisms and management of CAR T toxicity.
Ferreri CJ, Bhutani M. Ferreri CJ, et al. Among authors: bhutani m. Front Oncol. 2024 May 21;14:1396490. doi: 10.3389/fonc.2024.1396490. eCollection 2024. Front Oncol. 2024. PMID: 38835382 Free PMC article. Review.
617 results